Evidence map›Paper›PMID 35370654›Full record

ArticleFrontiers in pharmacology2022

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience.

Fengze Sun, Dawei Wang, Aina Liu, Tianqi Wang, Dongxu Zhang, Huibao Yao, Kai Sun, Zhongbao Zhou, Guoliang Lu, Jitao Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Fengze SunDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Dawei WangDepartment of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Aina LiuDepartment of Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Tianqi WangDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Dongxu ZhangDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Huibao YaoDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Kai SunDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Zhongbao ZhouDepartment of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Guoliang LuDepartment of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jitao WuDepartment of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Yuhuangding Hospital · CNQingdao University · CNRuijin Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse eventschemotherapyefficacyprogrammed death -1/programmed death ligand 1 (PD-1/PD-L1)urothelial carcinoma

Identifiers

PMID35370654
PMCPMC8971813
OpenAlexW4220745112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.